Menu
Exhalix develops non-invasive diagnostics and minimally invasive therapeutic technologies for detection and treatment of lower extremity vascular health.

Exhalix develops non-invasive diagnostics and minimally invasive therapeutic technologies for detection and treatment of lower extremity vascular health.

Exhalix develops non-invasive diagnostics and minimally invasive therapeutic technologies for detection and treatment of lower extremity vascular health.

Home

At Exhalix we are applying our experience in trace-level gas sensors, microfluidic systems, and microelectronic devices to develop breakthrough medical diagnostic and therapeutic products. We have partnered with leading research organizations to exploit important functions of the Hydrogen Sulfide (H2S) gasotransmitter molecule for diagnosis and therapy of endothelial dysfunction, the leading cause of lower extremity ischemia, peripheral artery disease (PAD), chronic wounds, and chronic limb threatening ischemia (CLTI). Endothelial dysfunction is caused by smoking, hyperglycemia, hypertension, and hyperlipidemia and highly prevalent among diabetic individuals.

Currently one out of 20 over the age of 50 and more than 6.5 million Americans suffer from peripheral artery and microvascular related disease, with a combined healthcare costs exceeding $21B.
Currently one out of 20 over the age of 50 and more than 6.5 million Americans suffer from peripheral artery and microvascular related disease, with a combined healthcare costs exceeding $21B.

At Exhalix we are applying our experience in trace-level gas sensors, microfluidic systems, and microelectronic devices to develop breakthrough medical diagnostic and therapeutic products. We have partnered with leading research organizations to exploit important functions of the Hydrogen Sulfide (H2S) gasotransmitter molecule for diagnosis and therapy of endothelial dysfunction, the leading cause of lower extremity ischemia, peripheral artery disease (PAD), chronic wounds, and chronic limb threatening ischemia (CLTI). Endothelial dysfunction is caused by smoking, hyperglycemia, hypertension, and hyperlipidemia and highly prevalent among diabetic individuals.

Currently one out of 20 over the age of 50 and more than 6.5 million Americans suffer from peripheral artery and microvascular related disease, with a combined healthcare costs exceeding $21B.
Currently one out of 20 over the age of 50 and more than 6.5 million Americans suffer from peripheral artery and microvascular related disease, with a combined healthcare costs exceeding $21B.

Hydrogen Sulfide is a Biomarker of Vascular Health

The important role of H2S and its deficiency in endothelial dysfunction has only been revealed during the past decade. Generated endogenously, normal levels of H2S regulate organ development and maintain homeostasis, while abnormal levels are associated with many cardiovascular and neurodegenerative diseases. Exhalix is exploiting the endogenous H2S bioavailability at the skin surface as a diagnostic tool and locally delivering low, sustained dose of exogenous H2S to the wounded tissue as a therapeutic agent to accelerate angiogenesis, revascularization, and wound healing.

From Detection to Therapeutics
From Detection to Therapeutics
Learn More About Hydrogen Sulfide

Non-Invasive Diagnostics

Rate of emission of endogenous H2S from the surface of the skin is used for evaluation of lower extremity vascular health.

Home
Learn More About TAGS™

Minimally Invasive Therapeutics

H2S deficiency is treated with the topical and implantable devices for chronic and surgical wound therapy.

Home
Learn More About HEALS™/ReLIS™

Non-Invasive Diagnostics

Rate of emission of endogenous H2S from the surface of the skin is used for evaluation of lower extremity vascular health.

Home
Learn More About TAGS™

Minimally Invasive Therapeutics

H2S deficiency is treated with the topical and implantable devices for chronic and surgical wound therapy.

Home
Learn More About HEALS™/ReLIS™

Partnership

Exhalix invites collaborators for clinical trials, product development, and commercialization

Partner with Us